Meeting
2014 ASCO Annual Meeting
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Authors
Belal Firwana
University of Missouri, Columbia, MO
Belal Firwana , Maria Diab , Mohamad Bassam Sonbol , Ibraheem Yousef , Rim Hasan , Shahzad Raza , Donald C. Doll
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7054)
DOI
10.1200/jco.2014.32.15_suppl.7054
Abstract #
7054
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren
Poster
2017 ASCO Annual Meeting
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
First Author: Hagop M. Kantarjian